The soluble form of TREM2 (sTREM2) is reported to be increased in the cerebrospinal fluid of patients with Alzheimer’s disease, multiple sclerosis, and neurosyphilis as a marker of microglial activation during neuroinflammation [28–33]. Here, TREM2 is linked to early-onset autosomal dominant Alzheimer disease.